STOKStoke Therapeutics, Inc.

STOK Stock Price, Valuation & Chart | Stoke Therapeutics, Inc.

Compare

$30.500-0.39 (-1.26%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology STOK intrinsic value STOK calculated fair value vs price

Overview Financials Dividends Ratios

STOK Historical price chart

STOK Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization1.97B

PE Ratio-9.13

EPS-3.34

Trading Volume630.56K

Today's High/Low32.12/29.96

Dividend Yield0.00

52 Week High/Low40.22/18.8

Shares Outstanding64.53M

STOK Financial Statement

STOK Analyst ratings

STOK Analysis & performance metrics

STOK Company profile

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic…

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001,…

STOK Management team

Name

Position

Barry S. Ticho FACC, M.D., Ph.D.

Chief Medical Officer

Doug SnowCTO

Director of Communications & Investor Relations

Dawn Kalmar

Chief Communications Officer

Arthur O. Tzianabos Ph.D.

Interim Executive Chairman

Isabel Aznarez Ph.D.

Co-Founder, Head of Research & Senior Vice President

Jonathan Allan J.D.

Corporate Secretary & General Counsel

Ian F. Smith A.C.A., C.P.A.CEO

Interim Chief Executive Officer & Director

Adrian R. Krainer Ph.D.CTO

Co-Founder & Independent Director

Name

Position

Barry S. Ticho FACC, M.D., Ph.D.

Chief Medical Officer

Doug SnowCTO

Director of Communications & Investor Relations

Dawn Kalmar

Chief Communications Officer

Arthur O. Tzianabos Ph.D.

Interim Executive Chairman

Isabel Aznarez Ph.D.

Co-Founder, Head of Research & Senior Vice President

Jonathan Allan J.D.

Corporate Secretary & General Counsel

Ian F. Smith A.C.A., C.P.A.CEO

Interim Chief Executive Officer & Director

Adrian R. Krainer Ph.D.CTO

Co-Founder & Independent Director

Management Team

Barry S. Ticho FACC, M.D., Ph.D.

Chief Medical Officer

Doug SnowCTO

Director of Communications & Investor Relations

Dawn Kalmar

Chief Communications Officer

Arthur O. Tzianabos Ph.D.

Interim Executive Chairman

Isabel Aznarez Ph.D.

Co-Founder, Head of Research & Senior Vice President

Jonathan Allan J.D.

Corporate Secretary & General Counsel

Ian F. Smith A.C.A., C.P.A.CEO

Interim Chief Executive Officer & Director

Adrian R. Krainer Ph.D.CTO

Co-Founder & Independent Director

Management

Barry S. Ticho FACC, M.D., Ph.D.

Chief Medical Officer

Doug SnowCTO

Director of Communications & Investor Relations

Dawn Kalmar

Chief Communications Officer

Arthur O. Tzianabos Ph.D.

Interim Executive Chairman

Isabel Aznarez Ph.D.

Co-Founder, Head of Research & Senior Vice President

Jonathan Allan J.D.

Corporate Secretary & General Counsel

Ian F. Smith A.C.A., C.P.A.CEO

Interim Chief Executive Officer & Director

Adrian R. Krainer Ph.D.CTO

Co-Founder & Independent Director

Total 8 executives

STOK Frequently asked questions

What is Stoke Therapeutics, Inc. (STOK) Stock Price?

Current stock price of Stoke Therapeutics, Inc. (STOK) stock is $30.500. The stock price is -1.26% lower in the session. The intraday range can be seen from this page. Volume of Stoke Therapeutics, Inc. (STOK) stock is 630.56K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Stoke Therapeutics, Inc. (STOK) stock price going up or down today?

The stock price of Stoke Therapeutics, Inc. (STOK) can change with earnings, company news, and overall market sentiment. Stoke Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Stoke Therapeutics, Inc. stock expensive at its current price?

Whether Stoke Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for STOK on this page is -9.13. EPS on this page is -3.34. Compare those figures with peers and growth expectations before deciding if the current Stoke Therapeutics, Inc. price is justified.

How has the stock price of Stoke Therapeutics, Inc. (STOK) performed historically?

Historical performance for Stoke Therapeutics, Inc. (STOK) is shown on the price chart on this page. Review multi-period moves alongside volume to see how STOK reacted to past earnings and market events.

Should I buy Stoke Therapeutics, Inc. (STOK) stock, at this price?

Buying Stoke Therapeutics, Inc. (STOK) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.